biostudies-literatureUnknownTorre PNICHD NIH HHS<h4>Background</h4>Few studies have evaluated the ototoxic effects of in utero antiretroviral (ARV) exposure on hearing in children HIV-exposed uninfected (CHEU). Concerns have been identified for some ARVs: tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), lamivudine (3TC), zidovudine (ZDV) and atazanavir (ATV). The aims are to describe hearing outcomes in 5-year-old CHEU in the Surveillance Monitoring for Antiretroviral Therapy Toxicities study and evaluate their association with in utero ARV exposures.<h4>Methods</h4>Hearing evaluations including pure-tone thresholds and distortion product otoacoustic emissions (DPOAEs) were completed in CHEU at 5 years. Log-binomial regression models were fit to assess associations of maternal ARV exposures with risk of sensorineural hearing loThe Pediatric infectious disease journalhttps://www.ebi.ac.uk/biostudies/studies/S-EPMC12790845biostudies-literatureHearing Measures in Children Perinatally HIV-exposed and Uninfected in the PHACS SMARTT Study.PMC12790845U01 HD052102P01 HD103133U01 HD052104Huldtquist JEser-Jose RPaul MMcFarland EMarullo DYao TJBettica LHickman PChadwick EFrederick TKohlhoff SHayani KWilkins MDeygoo NSPurswani MMorales-Avendano GPediatric HIV/AIDS Cohort StudyWallier JCuadra ALewis JKaye JLoughran MCraig KRichardson LGarcia GGTorre PCooley JDSurowiec KAngeli-Nieves LSpector SAWilliams PLGlenny CRathore MBaig MMHoffman HJDavtyan MSirag EJohnson JScott GTorres LRosario NDieudonne AHutto CLove SAlvarado MDennie AMahmoudi SSirois PFigueroa VOlivera VRodriguez ZMVillegas ABorkowsky WKnapp KRussell-Bell JMiller AGarvie PEnglund JMalee KMcMullen-Jackson CEl-Hassan SFernandez GNichols SSanders MABlood JKwon CRobinson LGZhang ZSmith RTejan JSilio MHarris LScalley NfalseHearing Measures in Children Perinatally HIV-exposed and Uninfected in the PHACS SMARTT Study.<h4>Background</h4>Few studies have evaluated the ototoxic effects of in utero antiretroviral (ARV) exposure on hearing in children HIV-exposed uninfected (CHEU). Concerns have been identified for some ARVs: tenofovir disoproxil fumarate (TDF), emtricitabine (FTC), lamivudine (3TC), zidovudine (ZDV) and atazanavir (ATV). The aims are to describe hearing outcomes in 5-year-old CHEU in the Surveillance Monitoring for Antiretroviral Therapy Toxicities study and evaluate their association with in utero ARV exposures.<h4>Methods</h4>Hearing evaluations including pure-tone thresholds and distortion product otoacoustic emissions (DPOAEs) were completed in CHEU at 5 years. Log-binomial regression models were fit to assess associations of maternal ARV exposures with risk of sensorineural hearing lo2025-01-01T00:00:00Z2025 Dec2026-06-06T11:28:14.077Z2026-05-29T03:13:16.896ZS-EPMC127908454135502910.1097/INF.000000000000509810.1097/inf.0000000000005098